Biofrontera AG

BFRA on NASDAQToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
11.05US -0.81/-6.83%50711.04 / 18.32247.61 M

Contact Information

Biofrontera AG

Headquarters:
Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
Germany, 51377
Tel: 49-214-87632-0
Email: Send a message
Website: Visit website
For more information...
Lead: Robert Thaemlitz

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer

Thomas Schaffer - Chief Financial Officer

Christoph Dünwald - Chief Compliance Officer

 

Ulrich Granzer, PhD. - Chairman

Jürgen Baumann - Vice Chairman of the Board

John Borer III, J.D. - Supervisory Board Member

Kevin Weber - Supervisory Board Member

Reinhard Eyring - Supervisory Board Member

Dr. Franca Ruhwedel - Director

Stock Information

Company Overview

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

Management

Prof. Dr. Rer. Nat. Hermann Lübbert - Chief Executive Officer

Thomas Schaffer - Chief Financial Officer

Christoph Dünwald - Chief Compliance Officer

 

Board of Directors

Ulrich Granzer, PhD. - Chairman

Jürgen Baumann - Vice Chairman of the Board

John Borer III, J.D. - Supervisory Board Member

Kevin Weber - Supervisory Board Member

Reinhard Eyring - Supervisory Board Member

Dr. Franca Ruhwedel - Director

Contact Information

Headquarters:
Hemmelrather Weg 201,
Leverkusen, North Rhine-Westphalia
51377, Germany
Telephone: 49-214-87632-0
Email: Send a message
Website: Visit website